Business Context and Reporting Period
This Form 8-K Current Report from Lifemd, Inc. (LFMD) covers the date of July 31, 2025. The filing primarily addresses corporate governance and executive compensation matters rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive appointments and compensation terms.
Material Changes
The primary material change reported is the appointment of Shayna Webb Dray as Chief Operating Officer (COO), effective March 27, 2025, publicly announced on July 31, 2025. Ms. Webb Dray previously served as Senior Vice President of Operations (September 2023 to July 2025) and Head of Supply Chain & Procurement (May 2021 to September 2023).
Guidance, Outlook, and Compensation Details
While no financial guidance is provided, the filing details significant compensatory arrangements tied to performance targets:
- Base Salary: $400,000 annually under a Third Amendment to her Employment Agreement.
- Equity Award: 100,000 Restricted Stock Units (RSUs) granted on July 27, 2025.
- Vesting Schedule:
- 10,000 RSUs vest on January 1, 2026.
- 20,000 RSUs vest on January 1, 2027.
- 20,000 RSUs vest on January 1, 2028.
- 50,000 RSUs (split into two tranches of 25,000) vest upon the Company's healthcare business achieving certain annualized EBITDA targets on or before December 31, 2027.
- Acceleration Provisions: Unvested time-based RSUs vest pro rata upon termination without "Cause" or for "Good Reason" if scheduled to vest within one year. All unvested RSUs vest immediately prior to a "Change of Control."
Investor Verification Checklist
- Verify the specific annualized EBITDA targets required for the vesting of 50,000 RSUs by reviewing the full text of the Restricted Stock Unit Award Agreement (Exhibit 10.5).
- Confirm the effective date of the COO appointment (March 27, 2025) against the announcement date (July 31, 2025) to understand the timeline of the leadership transition.
- Review the definitions of "Cause," "Good Reason," and "Change of Control" in the employment agreements to assess potential acceleration risks.
- Check subsequent filings for the impact of this leadership change on the Company's weight management program and operational scaling.